Johnson Matthey Catalysis and Chiral Technologies Introduces Catalytic Reaction Guide Mobile Application
Johnson Matthey Catalysis and Chiral Technologies (JMCCT), a business unit of Johnson Matthey Fine Chemical Division, has announced the launch of its Catalytic Reaction Guide (CRG) as a free mobile application. The app has been introduced to provide customers mobile access to catalyst recommendations on more than 150 chemical reactions in the area of homogeneous, heterogeneous and asymmetric catalysis. Users can easily view and search a full product listing with streamlined technical support, take advantage of an efficient quotation request process, and obtain contact information for a complete services offering.
As the only app of its kind on the market, JMCCT was motivated to make the guide mobile to enable informed purchasing decisions anywhere in the world. In addition to catalyst recommendations, the app features a convenient Chemical Abstracts Service searchable product listing and relevant literature references. The interface is fully customizable through a user profile that synchronizes data with other devices for easy tracking of recommendations and details.
“JMCCT strives to stay at the forefront of technology, not only in the products we offer, but in how we communicate with our customers. The CRG app is a cutting-edge, efficient means for customers to access catalytic reaction data, and tap into JMCCT’s technical knowledge on the go,” said Gerard Compagnoni, General Manager of Johnson Matthey Catalysis and Chiral Technologies. “We are very excited to introduce the app for the benefit of our customers, and are looking forward to shortly debuting the online version of the CRG to round out this resource.”
The migration to a digital platform was directly driven by customer demand for the CRG in a more manageable format than traditional print, and was formally completed and put into beta testing in late 2014. Customers may download the app for free on any iPhone, iPad or Android device. A complementary online CRG will go live on the JMCCT website in spring 2015.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance